Tyson Eliot Marshall Sells 88,835 Shares of Alphatec (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall sold 88,835 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $12.49, for a total transaction of $1,109,549.15. Following the sale, the general counsel owned 559,459 shares of the company’s stock, valued at $6,987,642.91. This trade represents a 13.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Alphatec Stock Down 2.8%

Shares of ATEC stock opened at $12.51 on Wednesday. The company has a current ratio of 2.06, a quick ratio of 1.28 and a debt-to-equity ratio of 40.35. Alphatec Holdings, Inc. has a 12 month low of $8.81 and a 12 month high of $23.29. The stock has a market cap of $1.89 billion, a P/E ratio of -13.17 and a beta of 1.02. The company has a 50 day simple moving average of $15.61 and a two-hundred day simple moving average of $16.96.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $212.93 million for the quarter, compared to analysts’ expectations of $212.67 million. The company’s revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.23) EPS. On average, research analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Trending Headlines about Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Quarterly results and analyst support: Alphatec beat Q4 EPS estimates and reported +20% revenue growth year‑over‑year (Feb. 24), and multiple firms maintain buy ratings; consensus price target remains materially above the current price (~$22.82). MarketBeat Coverage
• Positive Sentiment: Institutional accumulation: Several large funds (Millennium, Morgan Stanley, Tudor, Granite) materially increased stakes over recent quarters, signaling confidence from hedge funds/asset managers. Institutional Trading Details
• Neutral Sentiment: Analyst price‑target change: Stifel lowered its target from $24 to $20 but retained a Buy rating — still optimistic but less aggressive on upside. Benzinga Article
• Neutral Sentiment: Short interest postings show 0 shares / NaN changes for early March — likely a data or reporting quirk rather than a true change in short positioning; not meaningful by itself. (March 9–10 updates)
• Negative Sentiment: Insider selling by senior executives: General Counsel Tyson Eliot Marshall sold 88,835 shares at an average $12.49 (total ~$1.11M) and EVP Craig Hunsaker sold 33,602 and 82,765 shares on March 6 and March 9 (~$410k and ~$1.03M). These disclosures show notable reductions in insider holdings and are commonly viewed as near‑term negative signals. SEC filings: Marshall Form 4 and Hunsaker Form 4

Hedge Funds Weigh In On Alphatec

Several large investors have recently made changes to their positions in the business. Millennium Management LLC boosted its stake in shares of Alphatec by 292.2% in the fourth quarter. Millennium Management LLC now owns 2,225,927 shares of the medical technology company’s stock worth $46,834,000 after acquiring an additional 1,658,349 shares during the period. Granite Investment Partners LLC lifted its holdings in Alphatec by 320.6% in the 2nd quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company’s stock worth $19,102,000 after purchasing an additional 1,311,748 shares in the last quarter. Iron Triangle Partners LP purchased a new position in Alphatec in the 4th quarter worth approximately $27,051,000. Morgan Stanley boosted its stake in Alphatec by 22.0% in the 4th quarter. Morgan Stanley now owns 4,340,936 shares of the medical technology company’s stock worth $91,333,000 after purchasing an additional 784,191 shares during the period. Finally, Tudor Investment Corp ET AL boosted its stake in Alphatec by 608.4% in the 3rd quarter. Tudor Investment Corp ET AL now owns 900,491 shares of the medical technology company’s stock worth $13,093,000 after purchasing an additional 773,367 shares during the period. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on ATEC shares. Loop Capital set a $25.00 price target on Alphatec in a research report on Wednesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Alphatec in a research report on Monday, January 12th. Wall Street Zen upgraded Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, January 31st. Piper Sandler reissued an “overweight” rating on shares of Alphatec in a report on Wednesday, February 25th. Finally, TD Cowen restated a “buy” rating on shares of Alphatec in a research note on Tuesday, January 27th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $22.82.

Alphatec Company Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.